Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.

Kitazono-Saitoh M, Takiguchi Y, Kitazono S, Ashinuma H, Kitamura A, Tada Y, Kurosu K, Sakaida E, Sekine I, Tanabe N, Tagawa M, Tatsumi K.

Oncol Rep. 2012 Jul;28(1):33-40. doi: 10.3892/or.2012.1799. Epub 2012 May 4.

PMID:
22562354
2.

Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.

Gordon GJ, Mani M, Maulik G, Mukhopadhyay L, Yeap BY, Kindler HL, Salgia R, Sugarbaker DJ, Bueno R.

Cancer Chemother Pharmacol. 2008 Apr;61(4):549-58. Epub 2007 May 24.

PMID:
17522864
3.

Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.

Cortes-Dericks L, Carboni GL, Schmid RA, Karoubi G.

Int J Oncol. 2010 Aug;37(2):437-44.

PMID:
20596671
4.

Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation.

Cameron RB, Hou D.

J Thorac Cardiovasc Surg. 2013 Feb;145(2):496-504. doi: 10.1016/j.jtcvs.2012.10.042. Epub 2012 Nov 20.

5.

Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.

Zhang D, Ochi N, Takigawa N, Tanimoto Y, Chen Y, Ichihara E, Hotta K, Tabata M, Tanimoto M, Kiura K.

Cancer Lett. 2011 Oct 28;309(2):228-35. doi: 10.1016/j.canlet.2011.06.006. Epub 2011 Jun 24.

PMID:
21742432
6.

Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed.

Palumbo C, Battisti S, Carbone D, Albonici L, Alimandi M, Bei R, Modesti A.

Cancer Chemother Pharmacol. 2008 Apr;61(5):893-901. Epub 2007 Oct 6.

PMID:
17922127
7.

FDA drug approval summaries: pemetrexed (Alimta).

Hazarika M, White RM, Johnson JR, Pazdur R.

Oncologist. 2004;9(5):482-8. Review.

8.

Cytotoxic effects of pemetrexed in gastric cancer cells.

Kim JH, Lee KW, Jung Y, Kim TY, Ham HS, Jong HS, Jung KH, Im SA, Kim TY, Kim NK, Bang YJ.

Cancer Sci. 2005 Jun;96(6):365-71.

9.

Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.

Mairinger F, Vollbrecht C, Halbwedl I, Hatz M, Stacher E, Gülly C, Quehenberger F, Stephan-Falkenau S, Kollmeier J, Roth A, Mairinger T, Popper H.

J Thorac Oncol. 2013 May;8(5):644-53. doi: 10.1097/JTO.0b013e318287c224.

10.

TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.

Uramoto H, Onitsuka T, Shimokawa H, Hanagiri T.

Anticancer Res. 2010 Oct;30(10):4309-15.

PMID:
21036757
11.

Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma.

Vandermeers F, Hubert P, Delvenne P, Mascaux C, Grigoriu B, Burny A, Scherpereel A, Willems L.

Clin Cancer Res. 2009 Apr 15;15(8):2818-28. doi: 10.1158/1078-0432.CCR-08-1579. Epub 2009 Apr 7.

12.

Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.

Nagai S, Takenaka K, Sonobe M, Wada H, Tanaka F.

Chemotherapy. 2008;54(3):166-75. doi: 10.1159/000140360. Epub 2008 Jun 18.

PMID:
18560222
13.

Significance of thymidylate synthase for resistance to pemetrexed in lung cancer.

Ozasa H, Oguri T, Uemura T, Miyazaki M, Maeno K, Sato S, Ueda R.

Cancer Sci. 2010 Jan;101(1):161-6. doi: 10.1111/j.1349-7006.2009.01358.x. Epub 2009 Sep 10.

14.

Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells.

Buqué A, Aresti U, Calvo B, Sh Muhialdin J, Muñoz A, Carrera S, Azkona E, Rubio I, López-Vivanco G.

PLoS One. 2013 May 13;8(5):e63338. doi: 10.1371/journal.pone.0063338. Print 2013.

15.

Pemetrexed in malignant pleural mesothelioma.

Hazarika M, White RM Jr, Booth BP, Wang YC, Ham DY, Liang CY, Rahman A, Gobburu JV, Li N, Sridhara R, Morse DE, Lostritto R, Garvey P, Johnson JR, Pazdur R.

Clin Cancer Res. 2005 Feb 1;11(3):982-92.

16.

Pemetrexed (Alimta): improving outcomes in malignant pleural mesothelioma.

Budde LS, Hanna NH.

Expert Rev Anticancer Ther. 2004 Jun;4(3):361-8. Review.

PMID:
15161435
17.

Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.

[No authors listed]

Prescrire Int. 2005 Dec;14(80):212-4.

PMID:
16400741
18.

Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.

Hartman ML, Esposito JM, Yeap BY, Sugarbaker DJ.

J Thorac Cardiovasc Surg. 2010 May;139(5):1233-40. doi: 10.1016/j.jtcvs.2009.06.027. Epub 2009 Oct 22.

19.

Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells.

Maehara S, Usuda J, Ishizumi T, Ichinose S, Ohtani K, Inoue T, Imai K, Furumoto H, Kudo Y, Kajiwara N, Ohira T, Ikeda N.

Int J Oncol. 2015 Feb;46(2):741-9. doi: 10.3892/ijo.2014.2746. Epub 2014 Nov 10.

PMID:
25385189
20.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P.

J Clin Oncol. 2003 Jul 15;21(14):2636-44.

PMID:
12860938

Supplemental Content

Support Center